- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Poll
POLL: Which 2022 Psoriasis FDA Approval Were You Most Excited About?
Author(s):
Click here to answer this week's poll.
Which 2022 Psoriasis FDA Approval Were You Most Excited About?
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
Larry Eichenfield, MD: Safety, Convenience, and Future Role of Icotrokinra in Treating Adolescent Psoriasis
Future Directions for IL-17 Inhibitors in Psoriasis and Psoriatic Arthritis Care
Utility of Head-to-Head Studies in Psoriasis Management
Larry Eichenfield, MD: Icotrokinra Demonstrates Promising Results for Adolescents With Moderate to Severe Plaque Psoriasis
Long-Term Efficacy and Safety of IL-17 Inhibitors in Psoriasis
Hepatic Safety of IL-17 Inhibitors in Patients With Psoriasis
Safety Considerations for IL-17 Inhibitors
Selecting and Dosing IL-17 Inhibitors in Psoriasis
IL-17 Inhibitor Treatment Impact on Quality of Life in Psoriasis and Psoriatic Arthritis
Clinical Attributes of IL-17 Inhibitors in Psoriasis
Related Content
